Trials / Completed
CompletedNCT00581165
Study Evaluating Safety of Etanercept in Treatment of Patients With Moderate to Severe Psoriasiswith Etanercept
Evaluating Safety in Patients With Moderate to Severe Psoriasis Treated With Etanercept
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 500 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate (i) safety of etanercept in patients with moderate to severe psoriasis in Spain; (ii) the incidence of adverse events reported in these patients, and (iii) the role that age and concomitant therapy might play in the development of adverse reactions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Etanercept | recommended dose of enbrel is 25mg administered twice weekly. |
Timeline
- Start date
- 2006-02-01
- Primary completion
- 2007-08-01
- Completion
- 2007-08-01
- First posted
- 2007-12-27
- Last updated
- 2007-12-27
Source: ClinicalTrials.gov record NCT00581165. Inclusion in this directory is not an endorsement.